Carbylan Therapeutics Inc., of Palo Alto, Calif., reported top-line results from COR1.1, its first phase III trial of Hydros-TA, its formulation of hyaluronic acid which entraps low-dose corticosteroid triamcinolone acetonide, for the treatment of pain associated with osteoarthritis of the knee.